Thank And you, afternoon, everyone. good David.
the wound broad recognize to update that types. I As clinical SkinTE. generation the To is on key that we David meaningful you our based end, on would adoption mentioned, specific data like of of to progress
four, pilot studies slide data referenced positive publication DFU future. in are of expecting the data reported In near in from wounds, very our chronic the and we have previously VLU as and these
us Our to skin DFU key and feeling dialogue anticipate to the enrolling QX, half across pilot of will TU control in XXXX. interim the our data allow we the XX of related readout randomized meaningful is interim the is first actively that and during RCT combination published reimbursement have trial XXXX. of pairs data late sites, with the data It
expect XXXX. is interim in and the enrollment late to Our second we RCT ongoing, VLU also hit half of
centers very important focus area interest result, this spaces we heal chronic data encouraging. in to in And with hard of discussions of the and patient wound SkinTE generate results this for population Early pressure high to with challenging Another have population. are as in with key ulcers. and been a
wounds hope order half slide shown prospective five, in as We XX in study our initiate to proposition space, expect early to enhance of in we value XXXX. lower to trauma a to further in extremity, this in this traumatic wounds, XXXX. study first initiate Specific patient the
positive concluded head-to-head data anticipated interim trial. we year-end XXXX. this burns, had We presenting our by initially In have
are at on American now scheduling part of the data be conflicts targeting XXXX we meeting. to investigators, due the Association However, Burn March the presented the to the
The in a fine to board advisory helped which burn we off and country. feedback our of made created tune our of XXXX. study, burns half KOLs recently kick the informative burns, large meeting will the protocol initial first anticipate in was to has our for tune in from respected we and perspective top it accelerate highly the And from very up strategy SkinTE centers fine
to like transition now and research development activities. would our I to
stated accelerating growth number and remains priority. our As SkinTE earlier, of adoption one
As we we achieving projects prioritized believe have goal. assist that two slide in highlighted this six, will in
is The SkinTE cryo. first
to possibly substantiated working cryopreserve final our months that up have currently out We months. product for extend ability to and are SkinTE to to three six and XX
valuable multiple wounds. first, SkinTE one cryo multiple several us anticipate offer harvest. original instances from allow to a patient and being susceptible this chronic would to We offering deployments
in of large protocols. provider patient to with regimen. rehab due past wound patients suspect due non-compliance deployment location where stage or a require second prefer a a to Second, third, SkinTE in may circumstances that provider wounds might deployment And
finalize available SkinTE to our expect timeframe, We be in business cryo the model plan coming and launch and months. plan mid to the XXXX in
initial processing is for SkinTE the a of SkinTE device point-of-care. deployment immediately at Second, development a following the and potentially could of the point-of-care allow harvest that
early reporting progress prototypes, in updates While coming we working forward future and on and development look this made in stages, the project to have we moving towards of the quarters.
an to Lastly, active project unique dressing bioactive platform. our have we underway related development
few entire has on proud multiple times number and that the SkinTE won't remain the months. through list, you our finally, last are slide the over I work but that seven, the in continues build to evidence see received. by as can encouraged been we we recognized that awards read SkinTE scientific And has
summary, we're We on in execution the strategy R&D clinical shareholder am significantly remain encouraged value. areas will that in the In making of progress confident with the successful I our trials very future these front. enhance
for Paul turn financial like Mann call a to I'd to the over Now update.
